ClinicalTrials.Veeva

Menu

Supplemental Oxygen in Pulmonary Fibrosis

National Jewish Health logo

National Jewish Health

Status

Completed

Conditions

Pulmonary Fibrosis

Study type

Observational

Funder types

Other

Identifiers

NCT01961362
PCORI 4134a

Details and patient eligibility

About

To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change from before to after supplemental oxygen is prescribed.

Full description

The investigators aim to recruit patients with PF to participate in interviews and/or a one-year study of supplemental oxygen (O2). In the one-year study, the investigators will collect data before and for one year after PF patients are prescribed daily-use supplemental oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough, and day-to-day functioning before and after O2.

Enrollment

19 patients

Sex

All

Ages

18 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patient-Participants

(Using daily 02 therapy at time of enrollment)

  • Diagnosis of PF
  • Able to read and speak English
  • Has been on daily-use supplemental oxygen for more than one year

(Not using daily 02 therapy at time of enrollment)

  • Diagnosis of PF
  • Able to read, speak and write in English
  • Has not been prescribed daily-use supplemental oxygen
  • Forced vital capacity <75% and diffusing capacity <65% of predicted values
  • Subject's physician allows the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection

Primary Supporters

  • Self-report status of providing care or support to a person living with pulmonary fibrosis who has used supplemental oxygen for more than one year
  • Able to speak English

O2 Prescribers

  • Self-report status of being a prescriber of daily-use supplemental oxygen to PF patients
  • Able to speak English

Exclusion criteria

Patient-Participants (Using daily 02 therapy at time of enrollment)

  • No diagnosis of PF
  • Unable to read and speak English
  • Has been on daily-use supplemental oxygen for less than one year

(Not using daily 02 therapy at time of enrollment)

  • No diagnosis of PF
  • Unable to read, speak and write in English
  • Using supplemental oxygen during the day
  • Subject's physician does not allow the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection

Primary Supporters • Not meeting inclusion criteria

O2 Prescribers

• Not meeting inclusion criteria

Trial design

19 participants in 1 patient group

Pulmonary fibrosis patients
Description:
Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems